相关实验视频

Updated: Sep 18, 2025

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

贝瓦西祖马布在敏感的复发性上皮卵巢癌:一个风险分层分析

İrem Öner¹, Pınar Karaçin²

¹Department of Medical Oncology, Dr. Abdurrahman Yurtaslan Ankara Oncology Research and Training Hospital, Ankara 06200, Turkey.

Pharmaceuticals (Basel, Switzerland)

|June 27, 2025

概括

贝瓦西祖马布在高风险敏感性复发性卵巢癌 (PSROC) 患者中改善了生存率,但不是低风险患者. 这项研究使PSROC患者分层,以个性化治疗策略.

科学领域:

在瘤学瘤学.
妇科瘤学妇科瘤学
癌症治疗方法癌症治疗方法

背景情况:

卵巢上皮癌 (EOC) 是一种复杂的疾病,具有多种临床和分子特征,通常在晚期被诊断出来.
敏感性复发性卵巢癌 (PSROC) 由于耐药性和复发性而带来治疗挑战.
贝瓦西祖马布是一种抗血管性药物,用于PSROC,但其对风险群体的生存影响尚未完全理解.

研究的目的:

为了比较PSROC患者的高风险和低风险组的治疗反应.
评估贝瓦齐苏马布在这些风险层中对无进展生存期 (PFS) 和整体生存期 (OS) 的影响.
调查PSROC患者治疗反应,复发模式和存活率之间的关系.

主要方法:

对174名患有FIGOIII/IV期EOC的患者进行了回顾性研究,这些患者因PSROC而接受化疗或化疗加贝瓦西祖马布治疗.
根据临床病理学特征,患者被分为低风险和高风险组.
研究人员检查了生存分析 (PFS,OS) 和关于风险组和贝瓦西祖马布使用的不良事件.

主要成果:

低风险患者的PFS (13.7个月) 和OS (36.5个月) 比高风险患者 (PFS 10.8个月,OS 23.5个月) 长得多.
在低风险患者中,贝瓦齐祖马布显著改善了PFS (13.5 vs 9.7 个月),但没有OS (39.4 vs 33.3 个月).
在高风险患者中,贝瓦齐祖马布显著改善了PFS (13.9 vs 8.8个月) 和OS (36.5 vs 23.2个月).

结论:

这项研究基于使用真实数据的临床风险组和复发模式,独特地评估了PSROC中的bevacizumab有效性.
在高风险的PSROC患者中,贝瓦齐祖马布显示出显著的生存益处 (PFS和OS).
这些发现表明,风险分层对于在PSROC中个性化贝瓦西祖马布治疗策略至关重要.

关键词:

这是bevacizumab的治疗方法.细胞减小手术细胞减小手术高风险的高风险的风险.复发的位置复发的位置.低风险的低风险是什么对于白金敏感的敏感再发性上皮卵巢癌的卵巢癌.

更多相关视频

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1

Published on: December 5, 2020

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...